Abstract
Recently, several high-quality clinical randomized controlled trials (RCTs) have identified that cyclin-dependent kinases (CDKs) 4/6 inhibitors obtained a great safety and efficacy, which can be consequently applied as a combination therapy with letrozole or fulvestrant for women who had advanced breast cancer and progressed while receiving endocrine therapy. In this systemic review, we performed a meta-analysis to explore whether CDK4/6 inhibitors had a significantly benefit to treating hormone receptor-positive (HR-positive)/human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer. The data for meta-analysis were collected from MEDLINE, EMBASE, and Cochrane Library from January 1980 to December 2017, and eventually 3182 patients from 6 RCTs were included. The result showed the CDK4/6 inhibitor group had a longer progression-free survival (PFS) (hazard ratio = 0.51; 95% confidence interval [CI], 0.46-0.57, P < .00001), a better objective response (risk rate = 1.53; 95% CI, 1.35-1.74, P < .00001), as well as a better clinical benefit response (risk rate = 1.29; 95% CI, 1.13-1.47, P = .0001). Besides, subgroup analyses of PFS according to stratification factors and other baseline characteristics c...Continue Reading
References
Aug 30, 2000·Nature·C M PerouD Botstein
May 17, 2005·Lancet·UNKNOWN Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Mar 5, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen ChiaMartine Piccart
Oct 31, 2009·Breast Cancer Research : BCR·Richard S FinnDennis J Slamon
Sep 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angelo Di LeoMiguel Martin
Oct 5, 2010·Annual Review of Medicine·C Kent Osborne, Rachel Schiff
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Oct 4, 2011·The Journal of Clinical Investigation·Michaela J Higgins, José Baselga
Jan 12, 2012·British Journal of Cancer·A BerghoffR Bartsch
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
May 6, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mark A Dickson
Dec 20, 2014·The Lancet Oncology·Richard S FinnDennis J Slamon
Jun 2, 2015·The New England Journal of Medicine·Nicholas C TurnerUNKNOWN PALOMA3 Study Group
Mar 8, 2016·The Lancet Oncology·Massimo CristofanilliDennis Slamon
Mar 16, 2016·Cancer Cell·Shom GoelJean J Zhao
Mar 30, 2016·Cancer Research·Maria Teresa Herrera-AbreuVioleta Serra
Apr 1, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N HarbeckS Loibl
May 4, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maura N DicklerClifford A Hudis
Jun 24, 2016·The Breast : Official Journal of the European Society of Mastology·G CuriglianoS A Hurvitz
Nov 3, 2016·The New England Journal of Medicine·Gabriel N HortobagyiJoyce O'Shaughnessy
Oct 18, 2016·Oncogene·C YangS Chandarlapaty
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Apr 26, 2017·Journal of Hematology & Oncology·Hanxiao XuKongming Wu
Jun 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W SledgeAntonio Llombart-Cussac
Oct 3, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew P GoetzAngelo Di Leo
Citations
May 9, 2019·Breast Cancer Research and Treatment·Marina Elena CazzanigaUNKNOWN NetworkER+
Nov 14, 2019·Cancers·Valentina RossiAlessandra Fabi
Sep 10, 2020·International Journal of Molecular Sciences·Michela PiezzoMichelino De Laurentiis
Nov 13, 2020·Patient Preference and Adherence·Martine C MaculaitisMelissa Crastnopol
Jul 30, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold J BursteinHope S Rugo